Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
10 November 2020 - 10:06PM
Edgar (US Regulatory)
|
SEC FILE NUMBER
000-26770
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
|
¨ Form 10-K
|
¨ Form 20-F
|
¨ Form 11-K
|
x Form 10-Q
|
|
¨ Form 10-D
|
¨ Form N-CEN
|
¨ Form N-CSR
|
|
For Period Ended: September
30, 2020
¨
|
Transition Report on Form 10-K
|
¨
|
Transition Report on Form 10-Q
|
¨
|
Transition Report on Form 20-F
|
|
|
¨
|
Transition Report on Form 11-K
|
|
|
For the Transition Period Ended: ______________________________________________
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates: _____________________________________________________
PART I
REGISTRANT INFORMATION
NOVAVAX, INC.
|
Full Name of Registrant
|
|
Former Name if Applicable
|
|
21 Firstfield Road
|
Address of Principal Executive Office (Street and Number)
|
|
Gaithersburg, Maryland 20878
|
City, State and Zip Code
|
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate).
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without
unreasonable effort or expense.
|
x
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K,
Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion
thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
PART III
NARRATIVE
State below in reasonable detail why Forms
10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
Novavax, Inc. (the “Company”)
was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30,
2020 (the “Q3 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) by November 9, 2020. This
delay is attributable to technical issues that prevented final changes from being incorporated into the filing prior to the deadline
for submission.
The Company expects to file its Q3 Form
10-Q on or before the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25 under the Securities
and Exchange act of 1934, as amended.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
John A. Herrmann III
|
(240)
|
268-2000
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
(3) Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof?
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot
be made.
NOVAVAX,
INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 10, 2020
|
|
By:
|
/s/ John A. Herrmann III
|
|
|
Name:
|
John A. Herrmann III
|
|
|
Title:
|
Executive Vice President, Chief Legal Officer and Corporate Secretary
|
Exhibit A
The changes in the statement of operations of the Company were
those set forth in the press release of the Company dated November 9, 2020, which reported results for the period in question.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024